ASX Announcements
Application for quotation of securities - COH
Appendix 2A (Application for Quotation of Securities)
- Jan 30, 2025
- 7 pages
Notice of HY25 result analyst and media briefing
Notification of Results/Reporting Date, Web Casts
- Jan 20, 2025
- 1 page
Notification of cessation of securities - COH
Appendix 3H (Notification of cessation of securities)
- Dec 24, 2024
- 4 pages
Notification regarding unquoted securities - COH
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities)
- Dec 24, 2024
- 6 pages
Notification regarding unquoted securities - COH
Appendix 3G (Notification of Issue, Conversion or Payment up of Unquoted Equity Securities)
- Dec 24, 2024
- 7 pages
October 2024
Cochlear-backed medtech Epiminder seeks $200m val in pre-IPO raise
The company expects its implants to be commercially available in the US market in 2027.
- Sarah Thompson, Kanika Sood and Emma Rapaport
Unlikely winners of ATO’s R&D tax rules
The tax office’s first transparency report on R&D tax credits reveals the unlikely winners of the system.
- Mark Di Stefano
August 2024
Cochlear shares slide after missing market expectations
Cochlear says sales of its hearing implants globally will drive profit higher by between 6 per cent and 11 per cent this year.
- Updated
- Michael Smith
Jobless rate climbs; Telstra profits drop; KPMG partner pay slides
Read everything that’s happened in the news so far today.
May 2024
‘Business spends bugger all’: what landmark R&D review aims to fix
Technology industry experts warn a new government review into the R&D system must not cut tax incentives, and must kick-start anaemic business investment.
- Paul Smith, Tess Bennett and Nick Bonyhady
March 2024
- Opinion
- Chanticleer
Can a vaccine slow down the Cochlear train?
Cochlear is firing for investors, but you have to wonder whether everyone’s getting a bit carried away.
- Anthony Macdonald
February 2024
Cochlear’s big first half delivers record earnings and dividend
The company reported its best interim sales and underlying net profit thanks to strong growth for its core hearing implants and services.
- Ben Potter
Why analysts love these eight medtech stocks
The sector that straddles healthcare and tech has professionals searching for companies that could be tomorrow’s big winners after Pro Medicus.
- Tom Richardson
Cochlear lifts guidance despite Moderna vaccine threat
The hearing implant device maker’s shares rose more than 3 per cent after the company lifted its earnings forecasts.
- Liam Walsh
January 2024
This fundie blasted Rio Tinto – then doubled down on his investment
WaveStone Capital’s Raaz Bhuyan talks about his latest trip to the Pilbara and how he was horrified by the miner’s initial response to the Juukan Gorge scandal.
- Joanne Tran
December 2023
Schroders says Origin Energy assets ‘undervalued’
The head of Australian equities at the $1.3 trillion fund manager says returns in the energy sector will have to increase to attract more capital.
- Jonathan Shapiro
September 2023
Seven growth stocks for the next 10 years
To help navigate the volatile macro environment of high inflation and rising interest rates, we asked some of Australia’s best stock pickers for their longer-term standouts.
- Tom Richardson
August 2023
Technology float CurveBeam AI graduates to ASX
Medical software group Curvebeam AI hits the ASX boards on Wednesday, having won over fund managers from its pre-IPO days.
- Tom Richardson
Profit season hits and misses | Property’s big problems | Is US inflation fight over?
In this week’s episode, James and Anthony pick through the hits and misses of reporting season, take a deep dive into the property sector, and look ahead to the Jackson Hole conference.
- Opinion
- Chanticleer
Blue chip Cochlear lays down blue-chip result, gets more expensive
Globally relevant, strong sales growth and profit and net cash. What’s not to like at Cochlear? The question is whether you would pay nearly 50 times forecast profit for a piece of it.
- Anthony Macdonald
Cochlear investors hear siren call of higher profits
The hearing device maker, which grew profits but saw a margin squeeze, is forecasting a boost this year.
- Liam Walsh
June 2023
- Opinion
- Chanticleer
Why earnings season might be full of surprises (and shocks)
Consensus earnings estimates are looking stale, opening the door for August’s reporting season to deliver some real shocks.
- James Thomson
- Exclusive
- Tax avoidance
Labor bows to pressure on multinational tax disclosure
Amended legislation introduced to parliament on Thursday has wound back the plan significantly.
- Tom McIlroy
May 2023
- Opinion
- Chanticleer
Eight much-loved stocks that investors should worry about
Just as Wall Street is being pushed higher by a small group of big stocks, ASX investors have crowded into a handful of “diamond defensives”.
- James Thomson
- Opinion
- Ageing
Ways to invest in the Baby Boomer megatrend
With the population over 65 expected to grow at twice the rate of the Australian population, likely winners include healthcare companies and financial services.
- Mark Draper